PRPS1 and acute lymphoblastic leukemia: Our findings would bridge between PRPS1 mutant‐induced metabolic abnormality and prodrug activation of 5‐FU, suggesting a potential therapeutic strategy for drug resistant ALL patients with relapse‐specific PRPS1 mutations.